Inhibitex has received fast-track designation from the US Food and Drug Administration (FDA) for INX-08189, a guanosine nucleotide polymerase inhibitor intended to treat chronic hepatitis C.
Fast-track designation is designed to help the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions, and for drugs that show potential to address unmet medical needs.
The characteristics of INX-08189, including a high genetic barrier to resistance, its pan-genotypic activity, and once-daily oral dosing, facilitated the grant of fast-track designation.
The company has reported interim data from the first two cohorts of its ongoing Phase Ib clinical trial of INX-189, and it expects to complete the trial in the first quarter of 2011.
Hepatitis C is a disease of the liver that affects an estimated 4 million people in US and 170 million worldwide.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData